Clinical Trial

Pemafibrate To Reduce Cardiovascular Outcomes By Reducing Triglycerides In Patients With Diabetes (Protocol K-877-302, PROMINENT STUDY)

Study Status:

Contact Information:

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose

The purpose of this study is to find out if K-877 (also called pemafibrate), the study drug, compared to placebo (a treatment which looks like the medicine but contains no active pemafibrate), lowers cardiovascular (CV) complications (also referred to as “events”), such as heart attack, stroke and death from these conditions, in adults with type-2 diabetes mellitus (T2D) who have elevated triglycerides (TGs; one type of fat), and low high-density lipoprotein cholesterol (HDL-C; “good” cholesterol).


Principal Investigator Marcel B. Twahirwa, MD
Sponsor Kowa Research Institute, Inc. /USA
Type of Trial Interventional